Advertisement

 

 

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy.

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy.
Author Information (click to view)

Singini I, Campbell TB, Smeaton LM, Kumarasamy N, La Rosa A, Taejareonkul S, Safren SA, Flanigan TP, Hakim JG, Hughes MD, ,


Singini I, Campbell TB, Smeaton LM, Kumarasamy N, La Rosa A, Taejareonkul S, Safren SA, Flanigan TP, Hakim JG, Hughes MD, , (click to view)

Singini I, Campbell TB, Smeaton LM, Kumarasamy N, La Rosa A, Taejareonkul S, Safren SA, Flanigan TP, Hakim JG, Hughes MD, ,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

HIV clinical trials 2016 7 29() 1-8

Abstract
BACKGROUND
Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression.

METHODS
Participants were the 911 HIV-infected antiretroviral-naïve adults with CD4 count <300 cells/μL who started efavirenz-based ART in the international A5175/PEARLS trial and achieved HIV-1 RNA <1000 copies/mL at 24 weeks. Participant report of ART adherence was evaluated using a structured questionnaire in monthly interviews. Adherence and readily available clinical and laboratory measures were evaluated as predictors of late virologic failure (late VF: confirmed HIV-1 RNA ≥1000 copies/mL after 24 weeks). RESULTS
During median follow-up of 3.5 years, 82/911 participants (9%) experienced late VF. Of 516 participants reporting missed doses during the first 24 weeks of ART, 55 (11%) experienced late VF, compared with 27 (7%) of 395 participants reporting no missed doses (hazard ratio: 1.73; 95% CI: 1.08, 2.73). This difference persisted in multivariable analysis, in which lower pre-ART hemoglobin and absence of Grade ≥3 laboratory results prior to week 24 were also associated with higher risk of late VF.

DISCUSSION
In this clinical trial, the late VF rate after successful suppression was very low. If achievable in routine clinical practice, virologic monitoring involving infrequent (e.g. annual) measurements might be considered; the implications of this for development of resistance need evaluating. Patients reporting missed doses early after ART initiation, despite achieving initial suppression, might require more frequent measurement and/or strategies for promoting adherence.

Submit a Comment

Your email address will not be published. Required fields are marked *

14 − 13 =

[ HIDE/SHOW ]